Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 2;14:1183983. doi: 10.3389/fimmu.2023.1183983

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Serwanga, Baine, Mugaba, Ankunda, Auma, Oluka, Kato, Kitabye, Sembera, Odoch, Ejou, Nalumansi, Gombe, Musenero, Kaleebu and the COVID-19 Immunoprofiling Team

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Percentage of seropositive participants following vaccination. Figure 3 illustrates the proportion (%) of participants with spike-directed IgG (A), IgM (B), IgA (C), and anti-nucleoprotein IgM (D) ad IgG (E) antibodies at various follow-up time points after vaccination (x-axis). (F) is a bar graph depicting the proportion of breakthrough subjects, defined as those who experienced an 11-fold increase in the concentration of nucleoprotein-directed IgG antibodies at each time point.